Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion (FOV2302)

This study has been terminated.
Information provided by (Responsible Party):
Fovea Pharmaceuticals SA Identifier:
First received: August 31, 2009
Last updated: January 9, 2012
Last verified: January 2012
The purpose of the study is to evaluate the safety and tolerability of a single administration of FOV2302 (ecallantide) in patients with macular edema associated with central retinal vein occlusion.

Condition Intervention Phase
Macular Edema
Central Retinal Vein Occlusion
Drug: FOV2302 (Ecallantide)
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Dose Escalating Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion

Resource links provided by NLM:

Further study details as provided by Fovea Pharmaceuticals SA:

Primary Outcome Measures:
  • Safety and tolerability parameters to determine MTD: 1. Systemic parameters: adverse events (AEs), coagulation parameters (APTT, ACT) 2. Ophthalmologic parameters: BCVA, OCT, ocular inflammation, IOP [ Time Frame: 3 months post-dose ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Assess the pharmacodynamics up to five dose levels of a single administration of FOV2302 (ecallantide) by longitudinal measurements of the percent change of the macula thickness versus baseline as measured by OCT [ Time Frame: 3 months post-dose ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: September 2009
Estimated Study Completion Date: March 2012
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: FOV2302 (Ecallantide)

    Single intravitreal injection into the relevant eye.

    Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.

    Duration of Treatment: Single injection with 3 months follow-up.

Detailed Description:

Occlusive retinal vascular disease is not uncommon. Central retinal vein occlusion (CRVO) is the second most common vision-impairing vascular disorder of the retina following diabetic retinopathy. Severe visual loss from CRVO is caused by a combination of retinal edema and neovascular proliferation and ischemia. Vascular endothelial factors as they stimulate angiogenesis and increase vascular permeability, are majors pathogenic factors in CRVO. Counteracting these neovascular effects provide significant therapeutic benefit to subjects suffering from this disorder. Macular edema in this condition results from a conjunction of several, as yet, partially unknown factors.

Macular edema may occur in diseases causing cumulative injury over many years, such as diabetic retinopathy, or as a result of more acute events, such as branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Recent onset (< 6 months), non-ischemic CRVO (defined as association of documented retinal hemorrhage in all 4 quadrants of the retina with dilated veins) in patients who have not received treatment for their condition (e.g., no periocular depot or intraocular treatment [including corticosteroid and anti-VEGF], systemic corticosteroids or laser nor hemodilution).
  • Retinal thickness measured by Stratus OCT > 250µm in the central subfield of study eye at baseline.
  • BCVA score (measured by the ETDRS chart between 5 letters (20/800 Snellen equivalent) and 65 letters (20/50) in the study eye at baseline.
  • Media clarity, pupillary dilation and participant cooperation sufficient for adequate fundus photographs.
  • Females of childbearing potential using adequate birth control at Day 0 until study completion.
  • Patient able (in the opinion of the investigator) and willing to return for all scheduled visits and assessments.
  • Ability to read, understand and willingness to provide informed consent.

Exclusion Criteria:

  • Rubeosis iridis or neovascular glaucoma at baseline.
  • Preretinal neovascularisation at baseline.
  • Ischemic CRVO, defined by more than 10 disc area of non-perfusion on fluorescein angiography at baseline.
  • Any grade of diabetic retinopathy.
  • Other eye condition that could contribute to macular edema or cause retinal vascular changes (including vitreomacular traction, uveitis and inflammatory disease, etc).
  • Patients who have received treatment for their condition (e.g., no periocular depot or intraocular treatment [including corticosteroid and anti-VEGF], systemic corticosteroids or laser nor hemodilution).
  • Ocular surgery (including cataract extraction, scleral buckle, etc.) and/or YAG capsulotomy within 3 months preceding treatment date or anticipated within the 3 months following treatment administration.
  • Poorly controlled ocular hypertension and/or glaucoma (IOP greater than 25 mmHg despite maximal therapy).
  • History of pars plana vitrectomy.
  • Aphakia or anterior chamber intraocular lens.
  • Presence of visible sclera thinning or ectasia.
  • Presence of substantial cataract or other media opacity that, in the opinion of the investigator, is likely to interfere with visualization of the fundus or completion of study measurements.
  • Any active ocular or peri-ocular infection (including conjunctivitis, chalazion or significant blepharitis).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00969293

CHU d'Amiens, Centre Saint-Victor
Amiens, France, 80054
Centre Intercommunal de Creteil
Creteil, France, 94010
CHU de Dijon, Hôpital Général
Dijon, France, 21000
Clinique Monticelli
Marseille, France, 13008
CHU de Nantes
Nantes, France, 44093
Centre Hospitalier National d'Ophthalmologies des XV-XX
Paris, France, 75012
Hopital Lariboisiere
Paris, France, 75015
Fondation Rothschild
Paris, France, 75571
Sponsors and Collaborators
Fovea Pharmaceuticals SA
Study Chair: Alain Gaudric, MD Hopital Lariboisiere
  More Information

No publications provided

Responsible Party: Fovea Pharmaceuticals SA Identifier: NCT00969293     History of Changes
Other Study ID Numbers: FOV2302/CLIN/101/P 
Study First Received: August 31, 2009
Last Updated: January 9, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Fovea Pharmaceuticals SA:
Macular Edema
Occlusive retinal vascular disease
Central Retinal Vein Occlusion

Additional relevant MeSH terms:
Macular Edema
Retinal Vein Occlusion
Cardiovascular Diseases
Embolism and Thrombosis
Eye Diseases
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Signs and Symptoms
Vascular Diseases
Venous Thrombosis processed this record on February 11, 2016